{"title":"CYCLHAD:法国一家致力于强龙疗法研究和治疗的机构","authors":"F. Chevalier, P. Lesueur, G. Gaubert","doi":"10.1080/10619127.2022.2063002","DOIUrl":null,"url":null,"abstract":"Introduction For many years, the efforts to develop the hadrontherapy in Caen were made and supported by the Region Normandy. This hadrontherapy project, the Advanced Resource Center for Hadrontherapy in Europe (ARCHADE), described later, has led after many years of continuous efforts with partners to build its cornerstone: the CYCLHAD facility. CYCLHAD is a private company whose main shareholders are Ion Beam Applications (IBA; Louvain La Neuve), SAPHYN (a semipublic company based in Caen), and other private and clinical partners. The main purpose is to provide a cyclotrons-based facility for ion-beam therapy, starting with protons, and a multibeams research platform up to 400 MeV/n carbon beams. Thus, it is a dual-purpose building for healthcare and science. After an intensive planning period, at the end of 2014, CYCLHAD signed a contract awarded to the VINCI Group for the conception, construction, and maintenance of the building. At the same time, CYCLHAD contracted with IBA to acquire a ProteusOne® system together with its maintenance and operation. The construction of the main building started a year later and the beam was completed in September 2017. In parallel, IBA installed the Proteus-One®, which was delivered in May 2018. This proton facility is now clinically used by the anticancer center François Baclesse through an agreement to buy proton hours to CYCLHAD. The first treatment of a patient started in July 2018. To complete the facility, CYCLHAD appointed the Normandy Hadrontherapy company (NHa) to design and deliver the next cyclotronbased carbon facility (C400) through a contract signed in 2019. This new system, the Système de Recherche et de Traitement en Hadrontherapie (SRTH), will fit in the already built bunker (Figure 1), which is prepared to contain the C400 cyclotron accelerator and three beam-lines serving three clinical and experimental rooms (medical, radiobiology, and physics). First extracted beams are awaited around 2025–2026. CYCLHAD is also offering several hundreds of meter square of laboratories, which have to be equipped to host local groups and welcome visiting scientists.","PeriodicalId":38978,"journal":{"name":"Nuclear Physics News","volume":"341 1","pages":"27 - 31"},"PeriodicalIF":0.0000,"publicationDate":"2022-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"CYCLHAD: A French Facility Dedicated for Research and Treatment in Hadrontherapy\",\"authors\":\"F. Chevalier, P. Lesueur, G. Gaubert\",\"doi\":\"10.1080/10619127.2022.2063002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction For many years, the efforts to develop the hadrontherapy in Caen were made and supported by the Region Normandy. This hadrontherapy project, the Advanced Resource Center for Hadrontherapy in Europe (ARCHADE), described later, has led after many years of continuous efforts with partners to build its cornerstone: the CYCLHAD facility. CYCLHAD is a private company whose main shareholders are Ion Beam Applications (IBA; Louvain La Neuve), SAPHYN (a semipublic company based in Caen), and other private and clinical partners. The main purpose is to provide a cyclotrons-based facility for ion-beam therapy, starting with protons, and a multibeams research platform up to 400 MeV/n carbon beams. Thus, it is a dual-purpose building for healthcare and science. After an intensive planning period, at the end of 2014, CYCLHAD signed a contract awarded to the VINCI Group for the conception, construction, and maintenance of the building. At the same time, CYCLHAD contracted with IBA to acquire a ProteusOne® system together with its maintenance and operation. The construction of the main building started a year later and the beam was completed in September 2017. In parallel, IBA installed the Proteus-One®, which was delivered in May 2018. This proton facility is now clinically used by the anticancer center François Baclesse through an agreement to buy proton hours to CYCLHAD. The first treatment of a patient started in July 2018. To complete the facility, CYCLHAD appointed the Normandy Hadrontherapy company (NHa) to design and deliver the next cyclotronbased carbon facility (C400) through a contract signed in 2019. This new system, the Système de Recherche et de Traitement en Hadrontherapie (SRTH), will fit in the already built bunker (Figure 1), which is prepared to contain the C400 cyclotron accelerator and three beam-lines serving three clinical and experimental rooms (medical, radiobiology, and physics). First extracted beams are awaited around 2025–2026. CYCLHAD is also offering several hundreds of meter square of laboratories, which have to be equipped to host local groups and welcome visiting scientists.\",\"PeriodicalId\":38978,\"journal\":{\"name\":\"Nuclear Physics News\",\"volume\":\"341 1\",\"pages\":\"27 - 31\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-04-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nuclear Physics News\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/10619127.2022.2063002\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Physics and Astronomy\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nuclear Physics News","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/10619127.2022.2063002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Physics and Astronomy","Score":null,"Total":0}
引用次数: 1
摘要
多年来,卡昂的强韧疗法的发展得到了诺曼底大区的大力支持。这个强龙治疗项目,即欧洲强龙治疗高级资源中心(ARCHADE),经过多年与合作伙伴的持续努力,建立了它的基石:CYCLHAD设施。CYCLHAD是一家私营公司,其主要股东是Ion Beam Applications (IBA;Louvain La Neuve)、SAPHYN(一家位于卡昂的半上市公司)以及其他私人和临床合作伙伴。主要目的是为离子束治疗提供一个以回旋加速器为基础的设施,从质子开始,以及一个高达400 MeV/n碳束的多束研究平台。因此,它是一个医疗和科学双重用途的建筑。经过密集的规划期,在2014年底,CYCLHAD与VINCI集团签订了一份合同,负责该建筑的构思、建造和维护。与此同时,CYCLHAD与IBA签订合同,购买ProteusOne®系统及其维护和操作。主楼的建设在一年后开始,横梁于2017年9月完工。与此同时,IBA安装了Proteus-One®,该产品于2018年5月交付。通过向CYCLHAD购买质子小时的协议,该质子设备现在被抗癌中心franois Baclesse临床使用。患者的第一次治疗始于2018年7月。为了完成该设施,CYCLHAD通过2019年签署的合同委托诺曼底强子疗法公司(NHa)设计和交付下一个基于回旋加速器的碳设施(C400)。这个名为SRTH的新系统将安装在已经建成的掩体中(图1),该掩体准备容纳C400回旋加速器和三条光束线,服务于三个临床和实验房间(医学、放射生物学和物理学)。第一批提取的光束预计在2025-2026年左右。CYCLHAD还提供了几百平方米的实验室,这些实验室必须配备接待当地团体和欢迎来访的科学家的设备。
CYCLHAD: A French Facility Dedicated for Research and Treatment in Hadrontherapy
Introduction For many years, the efforts to develop the hadrontherapy in Caen were made and supported by the Region Normandy. This hadrontherapy project, the Advanced Resource Center for Hadrontherapy in Europe (ARCHADE), described later, has led after many years of continuous efforts with partners to build its cornerstone: the CYCLHAD facility. CYCLHAD is a private company whose main shareholders are Ion Beam Applications (IBA; Louvain La Neuve), SAPHYN (a semipublic company based in Caen), and other private and clinical partners. The main purpose is to provide a cyclotrons-based facility for ion-beam therapy, starting with protons, and a multibeams research platform up to 400 MeV/n carbon beams. Thus, it is a dual-purpose building for healthcare and science. After an intensive planning period, at the end of 2014, CYCLHAD signed a contract awarded to the VINCI Group for the conception, construction, and maintenance of the building. At the same time, CYCLHAD contracted with IBA to acquire a ProteusOne® system together with its maintenance and operation. The construction of the main building started a year later and the beam was completed in September 2017. In parallel, IBA installed the Proteus-One®, which was delivered in May 2018. This proton facility is now clinically used by the anticancer center François Baclesse through an agreement to buy proton hours to CYCLHAD. The first treatment of a patient started in July 2018. To complete the facility, CYCLHAD appointed the Normandy Hadrontherapy company (NHa) to design and deliver the next cyclotronbased carbon facility (C400) through a contract signed in 2019. This new system, the Système de Recherche et de Traitement en Hadrontherapie (SRTH), will fit in the already built bunker (Figure 1), which is prepared to contain the C400 cyclotron accelerator and three beam-lines serving three clinical and experimental rooms (medical, radiobiology, and physics). First extracted beams are awaited around 2025–2026. CYCLHAD is also offering several hundreds of meter square of laboratories, which have to be equipped to host local groups and welcome visiting scientists.